Latest News for: psma

Edit

NUCLIDIUM Announces Issuance of New U.S. Patent Covering its 61Cu-based Radiodiagnostic Program for PSMA-positive Prostate Cancer

Nasdaq Globe Newswire 26 Jan 2026
Patent for composition of matter & methods of use of high-radiopure diagnostic ⁶¹Cu-NU101 & combination use w/ 67Cu- therapeutic in PSMA+ prostate cancer ... .
Edit

PSMA-Targeted Therapy Market Set to Expand by 2034 on Strong Pipeline and Increasing Diagnosis Rates | DelveInsight

PR Newswire 20 Jan 2026
Learn more about the PSMA-targeted therapy @ PSMA-targeted Therapy Analysis ... The therapy targets PSMA by pairing a PSMA-selective ligand, PSMA-I&T, with no-carrier-added lutetium-177, a beta-emitting radioisotope ... Key PSMA-targeted Therapies.
Edit

Co-PSMA abstract accepted for oral presentation at EAU Annual Congress 2026

Image The Facts 24 Dec 2025
SYDNEY, Dec. 24, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX.
Edit

PSMA scheme saved 13k high-risk pregnant women in Mysuru district

The Times of India 13 Dec 2025
+Text SizeSmallMediumLarge. .
Edit

PSMA-Targeted Therapy & Radiodiagnostics Competitor Analysis Report 2025 - ResearchAndMarkets.com

Business Wire 02 Dec 2025
PSMA-Targeted Therapy & Radiodiagnostics" report has been added to ResearchAndMarkets.com's offering.
Edit

Summary report on authorisation – 18F-PSMA-1007 ZRP® (Swissmedic - Swiss Agency for Therapeutic Products)

Public Technologies 21 Nov 2025
11 June 2024 Solution for injection for the detection by imaging of PSMA-positive lesions in adults with prostate cancer About the medicinal product ...
Edit

Summary report on authorisation – SWAN-PSMA-1007® (Swissmedic - Swiss Agency for Therapeutic Products)

Public Technologies 30 Oct 2025
11 June 2024 Solution for injection for the detection by imaging of PSMA-positive lesions in adults with prostate cancer About the medicinal product ...
  • 1

Article Search

tools
×
×
×
×